Ocular Therapeutix, Inc. filed a current report on November 9, 2026, disclosing the election of Riad Sherif, M.D. to its Board of Directors effective November 6, 2026, and the forthcoming resignation of Seung Suh Hong, Ph.D., effective December 31, 2026.

Key Highlights

  • New director elected: Riad Sherif, M.D., age 58, was elected to the Board on November 6, 2026, as a Class I member to serve until the Company's 2027 annual meeting of stockholders.
  • Stock option grant: Dr. Sherif received an option to purchase 88,000 shares of common stock at an exercise price of $6.60 per share, the closing price on November 6, 2026.
  • RSU award: Dr. Sherif also received a restricted stock unit award for 28,000 shares of common stock, with both the option and RSU vesting annually over three years.
  • Director resignation: Seung Suh Hong, Ph.D. notified the Company of his resignation from the Board, effective December 31, 2026.
  • No disagreement: According to the filing, Dr. Hong's resignation "is not the result of any disagreement with the Board or with management on any matter relating to the Company's operations, policies or practices."
  • Current role: Dr. Sherif has served as Chief Executive Officer and board member of Oculis Holding AG since December 2017.

Board Change Details: Sherif Election and Hong Resignation at Ocular Therapeutix

Ocular Therapeutix, Inc. (NASDAQ:OCUL) disclosed two board-level changes in its November 9, 2026 filing. On November 6, 2026, the Board of Directors, acting on a recommendation from its Nominating and Corporate Governance Committee, elected Riad Sherif, M.D. as a Class I director. His term runs until the Company's 2027 annual meeting of stockholders and thereafter until a successor is elected, or until his earlier death, resignation, or removal, according to the filing.

Dr. Sherif, age 58, brings an extensive background in ophthalmology and pharmaceutical leadership. The filing notes he has served as Chief Executive Officer and a board member of Oculis Holding AG, a clinical-stage biopharmaceutical company, since December 2017. Prior roles cited in the filing include positions at Novartis AG spanning from January 2002 to March 2014, covering leadership in transplant and immunology, vaccines and diagnostics, and country-level management in Canada. He also served as Region President, Europe, Middle East and Africa, for Alcon from March 2014 to May 2016, and held roles at Sanofi from 1993 to 2000. He currently serves on the Board of Directors of Revenio Group Oyj since March 2022, the filing states.

In accordance with the Company's non-employee director compensation policy, Dr. Sherif received upon election an option to purchase 88,000 shares at $6.60 per share and a restricted stock unit award for 28,000 shares, both vesting annually over three years. The filing also states that Dr. Sherif entered into the Company's standard form of Indemnification Agreement. Separately, Seung Suh Hong, Ph.D. submitted his resignation from the Board on November 6, 2026, with an effective date of December 31, 2026. The filing explicitly states no disagreement with the Board or management prompted the departure.

What Was Disclosed

Ocular Therapeutix disclosed the Board election of Riad Sherif, M.D. on November 6, 2026, including his equity compensation, and the resignation of Seung Suh Hong, Ph.D. effective December 31, 2026, with the Company affirming no disagreement was involved.